FLUCLOXACILLIN GH flucloxacillin (as sodium) 500 mg capsule blister pack ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

flucloxacillin gh flucloxacillin (as sodium) 500 mg capsule blister pack

generic health pty ltd - flucloxacillin sodium monohydrate, quantity: 563.78 mg - capsule - excipient ingredients: indigo carmine; methyl hydroxybenzoate; propyl hydroxybenzoate; gelatin; magnesium stearate; titanium dioxide; purified water; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections including pneumonia, osteomyelitis, skin and soft tissue and wound infections, infected burns, cellulitis.

Flucloxacillin 250 mg Capsules आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

flucloxacillin 250 mg capsules

athlone laboratories ltd - flucloxacillin - capsule, hard - 250 milligram(s) - beta-lactamase resistant penicillins; flucloxacillin

Flucloxacillin 250 mg Capsules आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

flucloxacillin 250 mg capsules

athlone laboratories ltd - flucloxacillin - capsule, hard - 250 milligram(s) - beta-lactamase resistant penicillins; flucloxacillin

Flucloxacillin 500 mg capsules आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

flucloxacillin 500 mg capsules

athlone laboratories ltd - flucloxacillin - capsule, hard - 500 milligram(s) - beta-lactamase resistant penicillins; flucloxacillin

Flucloxacillin 250 mg Capsules आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

flucloxacillin 250 mg capsules

athlone pharmaceuticals limited - flucloxacillin - capsule, hard - beta-lactamase resistant penicillins; flucloxacillin

Flucloxacillin 500 mg capsules आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

flucloxacillin 500 mg capsules

athlone pharmaceuticals limited - flucloxacillin - capsule, hard - beta-lactamase resistant penicillins; flucloxacillin

Flucloxacillin (AFT) न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

flucloxacillin (aft)

aft pharmaceuticals ltd - flucloxacillin sodium monohydrate 272.6mg equivalent to flucloxacillin 250 mg;   - capsule - 250 mg - active: flucloxacillin sodium monohydrate 272.6mg equivalent to flucloxacillin 250 mg   excipient: colloidal silicon dioxide gelatin magnesium stearate

Flucloxacillin (AFT) न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

flucloxacillin (aft)

aft pharmaceuticals ltd - flucloxacillin sodium monohydrate 545.3mg equivalent to flucloxacillin 500 mg;   - capsule - 500 mg - active: flucloxacillin sodium monohydrate 545.3mg equivalent to flucloxacillin 500 mg   excipient: colloidal silicon dioxide gelatin magnesium stearate

DICLOXACILLIN SODIUM capsule संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

dicloxacillin sodium capsule

a-s medication solutions - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility  testing ). dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. the penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. dicloxacillin sodium is contraindicated in persons who have shown hypersensitivity to any of the penicillins or any component of the formulations.